Analysts See $-0.26 EPS for Alkermes Plc (ALKS)

July 18, 2017 - By Clifton Ray

 Analysts See $ 0.26 EPS for Alkermes Plc (ALKS)
Investors sentiment decreased to 0.91 in 2016 Q4. Its down 0.29, from 1.2 in 2016Q3. It turned negative, as 26 investors sold Alkermes Plc shares while 96 reduced holdings. 44 funds opened positions while 67 raised stakes. 138.80 million shares or 2.08% more from 135.97 million shares in 2016Q3 were reported.
Assetmark Inc reported 0% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Boston Private Wealth Ltd Limited Liability Company reported 0.01% stake. Goldman Sachs Incorporated has invested 0.03% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Insight Cap Rech & Management has invested 0.16% in Alkermes Plc (NASDAQ:ALKS). Massachusetts-based Panagora Asset Mngmt has invested 0.04% in Alkermes Plc (NASDAQ:ALKS). Apg Asset Nv holds 167,191 shares or 0.02% of its portfolio. Blackrock reported 991,335 shares stake. Millennium Mgmt Ltd Liability Corp invested 0.21% in Alkermes Plc (NASDAQ:ALKS). 330,411 are owned by Mitsubishi Ufj. Trillium Asset Mgmt Ltd Liability Corporation reported 44,489 shares stake. Pnc Services Gp, a Pennsylvania-based fund reported 7,062 shares. 942,034 are held by Frontier Capital Limited Liability Corporation. Marshall Wace Ltd Liability Partnership holds 0.23% or 639,670 shares. Northwestern Mutual Wealth Mgmt reported 0% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Castleark Mgmt Limited Liability Company accumulated 43,490 shares or 0.08% of the stock.

Wall Street await Alkermes Plc (NASDAQ:ALKS) to release earnings on July, 27. Analysts forecast earnings per share of $-0.26, down exactly $0.08 or 44.44 % from 2014’s $-0.18 EPS. After posting $-0.31 EPS for the previous quarter, Alkermes Plc’s analysts now forecast -16.13 % EPS growth. The stock increased 1.36% or $0.8 during the last trading session, reaching $59.66. About 935,606 shares traded or 7.74% up from the average. Alkermes Plc (NASDAQ:ALKS) has risen 47.50% since July 18, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Among 11 analysts covering Alkermes (NASDAQ:ALKS), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Alkermes had 22 analyst reports since September 1, 2015 according to SRatingsIntel. The stock of Alkermes Plc (NASDAQ:ALKS) earned “Buy” rating by Evercore on Thursday, May 26. The firm earned “Market Perform” rating on Tuesday, June 13 by Leerink Swann. Barclays Capital maintained the stock with “Overweight” rating in Friday, July 29 report. Leerink Swann maintained the stock with “Outperform” rating in Friday, October 21 report. The firm has “Overweight” rating given on Friday, October 21 by JP Morgan. The firm has “Market Perform” rating given on Tuesday, July 26 by Cowen & Co. On Wednesday, July 13 the stock rating was maintained by Barclays Capital with “Overweight”. The rating was maintained by Jefferies on Friday, October 21 with “Buy”. The firm earned “Neutral” rating on Thursday, January 21 by JP Morgan. Jefferies maintained the shares of ALKS in report on Tuesday, June 6 with “Buy” rating.

Alkermes plc is a biopharmaceutical company. The company has market cap of $9.15 billion. The Firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

More notable recent Alkermes Plc (NASDAQ:ALKS) news were published by: which released: “Alkermes Preliminary Phase 3 Data Leaves A Welcomed Impression” on July 05, 2017, also with their article: “Alkermes Plc (ALKS) Q4 2016 Results – Earnings Call Transcript” published on February 15, 2017, published: “Alkermes May Have Lucky Investors Doing A Happy Jig” on June 20, 2017. More interesting news about Alkermes Plc (NASDAQ:ALKS) were released by: and their article: “Alkermes Data Don’t Enlighten” published on June 30, 2017 as well as‘s news article titled: “Alkermes plc (ALKS) Reports Positive Preliminary Topline Results From Phase 3 …” with publication date: June 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.